Target intelligence / Profile preview

Transportin-2 (TNPO2)

Target
TNPO2
Molecular classification
Karyopherin, Nuclear transport receptor, Importin, Biportin, Transporter
01

Overview

Transportin-2 (TNPO2) is a highly conserved nuclear transport receptor of the karyopherin/importin-β superfamily that mediates the import and shuttling of proteins between the cytoplasm and nucleus through the nuclear pore complex[1][2][3][4]. TNPO2 recognizes and binds proteins with specific nuclear localization signals, especially PY-NLS motifs and arginine-glycine-glycine (RGG) domains, and facilitates their RanGTP-dependent passage into the nucleus[1][2]. It shares high sequence and functional similarity with Transportin-1 (TNPO1) but has specificity for different cargos, including proteins involved in DNA repair and high mobility group (HMG) proteins[1]. TNPO2 also acts as a cytoplasmic retention factor for certain cargoes, such as estrogen receptor α (ERα), competing with other importins to regulate nuclear-cytoplasmic distribution and subsequent signaling activity[3]. Impairment of TNPO2 function is associated with protein aggregation, particularly in neurons, and has been linked to neurodegenerative disease and developmental disorders[1][2]. No clinically established drugs are known to robustly target TNPO2, and it is not currently a common therapeutic target, but its essential role in nucleocytoplasmic transport implicates it in a broad range of cellular and disease processes[1][2][3].

Other names
Importin 3Karyopherin beta-2bIPO3KPNB2BTRN2FLJ12155
02

Mechanism of action

RanGTP-dependent nucleocytoplasmic transport, Competitive inhibition of importin α/β1 pathway, Cytoplasmic retention of cargo proteins

03

Biological functions

Nuclear protein importNucleocytoplasmic transportNuclear localization signal (NLS) bindingRegulation of protein localizationNegative regulation of muscle cell differentiation
04

Disease associations

Neurodegenerative diseaseIntellectual developmental disorder with hypotonia/impaired speech/dysmorphic faciesEpilepsyCancer (by implication in protein mislocalization and aggregation)Other
05

Safety considerations

No specific safety concerns documented for targeting TNPO2, but functional impairment linked to protein aggregation in neurons and developmental/tissue disorders

Beyond the preview

Go deeper on Transportin-2 (TNPO2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transportin-2 (TNPO2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call